Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $17.76 + 0.33 (1.89%)
ExchangeNASDAQ
Volume153,951
Today's Open$17.67
Previous Close$17.43
Data as of 11/14/18 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $17.76 with a 52 week high of $25.17 and a 52 week low of $7.60.

Recent News

October 31, 2018

Nuvectra® to Participate in Two Upcoming Investor Conferences

PLANO, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two upcoming investor conferences. Event:   2018 Stephens NY Investment Conference Date:   Tuesday, November 6, 2018 Time:   9:00 a.m. E

Read More >

October 29, 2018

Nuvectra® Reports Third Quarter 2018 Financial Results

Reports Record Algovita® Sales of $12.5 million, Up 98% YoY PLANO, Texas, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the third quarter ended September 30, 2018. Highlights Record consolidated revenues of $14.2 million, up 87% YoY Consolidated gross margin increased to 54%, up from 46% in the third quarter of 2017 Completed secondary offering with net proceeds of $64.6 milli

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
DateTitle
11/28/18 11:30 a.m. ET
Nuvectra at Piper Jaffray Healthcare Conference
Location Lotte New York Palace Hotel, New York